menu
    • menu
    [{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"DF\/Net Research | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syntrix Pharmaceuticals \/ DF\/Net Research | National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Syntrix Pharmaceuticals \/ DF\/Net Research | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syntrix Pharmaceuticals \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"PRA Health Sciences | DF\/Net Research | ITT Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syntrix Pharmaceuticals \/ PRA Health Sciences | DF\/Net Research | ITT Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ PRA Health Sciences | DF\/Net Research | ITT Research Institute"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Celerion | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Celerion | National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ Celerion | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Neurology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Desmetramadol

    Menu

    Desmetramadol

    DEVELOPMENTS

    DIGITAL CONTENT

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Celerion | National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subje...

                            Details : Desmetramadol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 24, 2020

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Celerion | National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Desmetramadol is G-Protein Biased Opioid Receptor Agonist: Syntrix

                            Details : Findings could put desmetramadol in pivotal high-value position for safer opioid prescribing.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2020

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : DF/Net Research | National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

                            Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Neuropathies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2018

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : DF/Net Research | National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : PRA Health Sciences | DF/Net Research | ITT Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

                            Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2017

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : PRA Health Sciences | DF/Net Research | ITT Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed

                            Syntrix Pharmaceuticals

                            U.S.A arrow
                            DDL Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Omnitram Pharmacokinetic Study In Healthy Volunteers

                            Details : Omnitram is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 31, 2014

                            Lead Product(s) : Desmetramadol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth